Strides Pharma Science's Q1 FY 2025-26 Quarterly Results

Result Summary

• Strides Pharma Science Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.6%.
• Its expenses for the quarter were up by 1.4% QoQ and down 0.1% YoY.
• The net profit increased 910.4% QoQ and increased 54.6% YoY.
• The earnings per share (EPS) of Strides Pharma Science Ltd stood at 10.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Strides Pharma Science Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in the healthcare sector, focusing on producing generic pharmaceutical products, which are distributed globally. Strides Pharma is known for its extensive portfolio that includes both prescription and over-the-counter medications. The company has been actively involved in expanding its market reach and enhancing its product offerings. Recent developments may involve strategic partnerships, acquisitions, or expansions to strengthen its position in the pharmaceutical industry. However, specific details regarding recent major developments are not available in the provided data.

Revenue

For the first quarter of the fiscal year 2026 (Q1FY26), Strides Pharma Science Ltd reported a total income of ₹1128.32 crores. This represents a quarter-over-quarter (QoQ) increase of 5.4% compared to ₹1070.49 crores in the fourth quarter of FY25 (Q4FY25). On a year-over-year (YoY) basis, there is a 2.6% increase from ₹1100.22 crores recorded in the first quarter of FY25 (Q1FY25). The growth in total income over both the previous quarter and the previous year suggests an upward trend in revenue for the company during this period.

Profitability

The profitability metrics for Strides Pharma Science Ltd in Q1FY26 show a significant improvement. The company recorded a profit before tax (PBT) of ₹121.94 crores, which is a 55.9% increase QoQ from ₹78.20 crores in Q4FY25 and a 25.7% increase YoY from ₹96.98 crores in Q1FY25. The profit after tax (PAT) also saw a substantial rise to ₹105.59 crores, reflecting an extraordinary QoQ increase of 910.4% from ₹10.45 crores in the preceding quarter and a 54.6% increase YoY from ₹68.31 crores in the same quarter the previous year. The tax expense decreased by 14.5% QoQ to ₹16.45 crores from ₹19.25 crores in Q4FY25, while it showed a 2.4% YoY decrease from ₹16.86 crores in Q1FY25. Earnings per share (EPS) increased significantly to ₹10.80, marking a 440.0% QoQ rise from ₹2.00 and a 42.1% YoY increase from ₹7.60.

Operating Metrics

Analyzing the operating metrics, total expenses for Strides Pharma Science Ltd in Q1FY26 amounted to ₹998.01 crores, which is a 1.4% increase QoQ from ₹984.22 crores and a slight decrease of 0.1% YoY from ₹999.50 crores. This indicates a stable cost structure with a marginal increase in operating expenses over the recent quarter. The company's ability to control expenses while achieving revenue growth is reflected in the higher profitability margins. The data highlights the company's operational efficiency and its impact on overall financial performance. Specific financial ratios like P/E ratio, debt-to-equity ratio, or current ratio are not provided in the data, but the significant increase in profits and controlled expenses suggest a healthy operational environment for the company.